![](https://www.microbiometimes.com/wp-content/uploads/2022/04/shutterstock_1613697604-326x245.jpg)
Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis
Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]